1-Boc-4-(2-吡啶氧基)哌啶 | 313490-35-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-Boc-4-(2-吡啶氧基)哌啶
• 中文别名: 1-BOC-4-(2-吡啶基氧基)哌啶；1-Boc-4-(2-吡啶基氧基)哌啶
• 英文名称: tert-butyl 4-(pyridin-2-yloxy)piperidine-1-carboxylate
• 英文别名: tert-butyl 4-(2-pyridyloxy)piperidine-1-carboxylate；tert-butyl 4-(pyridine-2-oxy)piperidine-1-carboxylate；4-(pyridin-2-yloxy)-piperidine-1-carboxylic acid tert-butyl ester；tert-butyl 4-(2-pyridyloxy)-1-piperidinecarboxylate；1-tert-butoxycarbonyl-4-(2-pyridinyloxy)piperidine；1-Boc-4-(2-pyridyloxy)piperidine；tert-butyl 4-pyridin-2-yloxypiperidine-1-carboxylate
• CAS: 313490-35-6
• 化学式: C₁₅H₂₂N₂O₃
• 分子量: 278.351
• InChiKey: LYGIBBFCSCAULH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  51.7
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 储存条件：
  室温且干燥

反应信息

• 作为反应物：
  描述：

  1-Boc-4-(2-吡啶氧基)哌啶 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 4-(pyridin-2-yloxy)piperidine-1-carbonyl chloride
  参考文献：
  名称：

  PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

  摘要：

  这项发明涉及USP7抑制剂，用于治疗癌症、神经退行性疾病、免疫紊乱、炎症性疾病、心血管疾病、缺血性疾病、病毒感染和疾病、细菌感染和疾病，具有以下结构式： 其中m、n、X1、X2、R1-R5、R5'和R6如本文所述。

  公开号：

  US20160185785A1
• 作为产物：
  描述：

  2-氯吡啶 、 N-Boc-4-羟基哌啶 在 18-冠醚-6 作用下， 以 甲苯 为溶剂， 反应 18.0h， 生成 1-Boc-4-(2-吡啶氧基)哌啶
  参考文献：
  名称：

  WO2006/46031

  摘要：

  公开号：

文献信息

• [EN] 3-HETEROCYCLYL-4-PHENYL-TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN V1A RECEPTOR<br/>[FR] DERIVES 3-HETEROCYCLYL-4-PHENYL-TRIAZOLE COMME INHIBITEURS DE LA VASOPRESSINE PAR RECEPTEUR
  申请人：PFIZER LTD

  公开号：WO2005105779A1

  公开（公告）日：2005-11-10

  Compounds of formula (I): or a pharmaceutically acceptable derivative thereof, wherein R represents C1-6alkyl (optionally substituted by C1-6alkyloxy or Het) or C1-6alkyloxy; R1 and R2 independently represent hydrogen, halo or C1-6alkyl, ring A represents Het1; X represents O or NR3; R3 represents hydrogen or C1-6alkyl; ring B represents a phenyl group or Het2, either of which may be optionally substituted with one or more groups selected from halo, CN, C1-6alkyloxy, CF3, C1-6alkyl, NH2 and NO2; Het and Het1 independently represent a 5- or 6-membered saturated, partially unsaturated or aromatic heterocyclic group comprising either (a) 1 to 4 nitrogen atoms, (b) one oxygen or one sulphur atom or (c) 1 oxygen atom or 1 sulphur atoms and 1 or 2 nitrogen atoms are useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis) mittlesmerchz, preclampsia, premature ejaculation, premature (preterm) labour and Raynaud’s disease.

  式(I)的化合物：或其药学上可接受的衍生物，其中R代表C1-6烷基（可选地被C1-6烷氧基或Het取代）或C1-6烷氧基；R1和R2独立地代表氢、卤素或C1-6烷基，环A代表Het1；X代表O或NR3；R3代表氢或C1-6烷基；环B代表苯基或Het2，其中任一者可选地被一个或多个从卤素、CN、C1-6烷氧基、CF3、C1-6烷基、NH2和NO2中选择的基团取代；Het和Het1独立地代表含有（a）1至4个氮原子、（b）一个氧原子或一个硫原子或（c）1个氧原子或1个硫原子和1或2个氮原子的5-或6元饱和、部分不饱和或芳香杂环基团，对于治疗焦虑、心血管疾病（包括心绞痛、动脉粥样硬化、高血压、心力衰竭、水肿、高钠血症）、月经痛（原发性和继发性）、子宫内膜异位症、呕吐（包括晕动病）、子宫内生长迟缓、炎症（包括类风湿关节炎）、中间痛、子痫前症、早泄、早产、雷诺氏病等疾病有用。
• Cyclic amine compounds as CCR5 antagonists
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06562978B1

  公开（公告）日：2003-05-13

  A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R1 and R2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N+—R5.Y−(R5 is a hydrocarbon group; Y− is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO2; G2 is CO, SO2, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G1 is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).

  式（I）的化合物（其中R1是氢原子，可能被取代的碳氢基团，可能被取代的非芳香杂环基团，R2是可能被取代的碳氢基团，可能被取代的非芳香杂环基团，或R1和R2可以彼此结合与A一起形成可能被取代的杂环基团；A是N或N+—R5.Y−（R5是碳氢基团；Y−是一个对离子）；R3是可能被取代的环烃基团或可能被取代的杂环基团；n为0或1；R4是氢原子，可能被取代的碳氢基团，可能被取代的杂环基团，可能被取代的烷氧基团，可能被取代的芳基氧基团，或可能被取代的氨基团；E是可能被除氧以外的基团取代的二价脂肪族碳氢基团；G1是键，CO或SO2；G2是CO，SO2，NHCO，CONH或OCO；J是亚甲基或氮原子；Q和R中的每一个是键或可能被取代的二价C1-3脂肪族碳氢基团；条件是当G2为OCO时J为亚甲基，当另一个为键时Q和R中的一个不是键，当G1为键时Q和R中的每一个都不被氧基取代）或其盐具有强大的CCR5拮抗活性，并可优势用于治疗或预防人类体内各种HIV引起的传染病（例如艾滋病）。
• ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF
  申请人：Samumed, LLC

  公开号：US20170313682A1

  公开（公告）日：2017-11-02

  Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  揭示了用于治疗各种疾病和病理的异喹啉化合物。更具体地，本发明涉及使用异喹啉化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成、纤维化疾病、骨骼或软骨疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经病理条件/障碍/疾病。还提供了治疗与Wnt相关疾病状态的方法。
• Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles
  作者：Lu Xiong、Chao Gao、Yao-Jie Shi、Xin Tao、Juan Rong、Kun-Lin Liu、Cui-Ting Peng、Ning-Yu Wang、Qian Lei、Yi-Wen Zhang、Luo-Ting Yu、Yu-Quan Wei

  DOI：10.1039/c8ra00720a

  日期：——

  excellent antitubercular activity and low cytotoxicity. Several of the compounds showed improved microsomal stability and lower plasma protein-binding, opening a new direction for further lead optimization. And we obtained compound 3o, which maintained good anti-tuberculosis activity (MIC = 8 nM) and presented better in vitro ADME/T and in vivo pharmacokinetic profiles than reported BTZ compound PBTZ169

  硝基苯并噻嗪酮 (BTZ) 是一种很有前途的支架，通过抑制十异戊二烯基磷酰基-β- D-核糖 2′-氧化酶 (DprE1)，具有有效对抗结核分枝杆菌的活性。但不利的耐久性给此类药物的进一步开发带来了挑战。在此，设计并合成了一系列在C-2位带有多种不同取代基的BTZ。筛选了化合物对结核分枝杆菌H37Ra 的抗分枝杆菌活性，并对其代谢稳定性、血浆蛋白结合能力和体内药代动力学进行了分析。总的来说，这些含有N-哌嗪、 N-哌啶或N-哌啶酮部分的新型BTZ具有优异的抗结核活性和较低的细胞毒性。其中几种化合物表现出改善的微粒体稳定性和较低的血浆蛋白结合，为进一步先导化合物优化开辟了新方向。我们获得了化合物3o ，其保持了良好的抗结核活性（MIC = 8 nM），并且比报道的 BTZ 化合物PBTZ169表现出更好的体外ADME/T 和体内药代动力学特征，可作为治疗结核病的候选药物。
• Peptide compounds
  申请人：——

  公开号：US20040097425A1

  公开（公告）日：2004-05-20

  The present invention relates to a compound of the formula (I)wherein R1 is benzofuranyl substituted by halogen, or styryl substituted by halogen; R2 is substituted hydroxy, substituted mercapto or substituted sulfonyl; and X is or pharmaceutically acceptable salts thereof. The compound (1) of the present invention and pharmaceutically acceptable salts thereof possess a strong inhibitory activity on the production of nitric oxide (NO), and are useful for prevention and/or treatment of NO-mediated diseases in human being and animals. 1

  本发明涉及一种化合物，其化学式为（I），其中R1为被卤素取代的苯并呋喃基或被卤素取代的苯乙烯基；R2为取代羟基、取代巯基或取代磺酰基；X为或其药用可接受盐。本发明的化合物（1）及其药用可接受盐对一氧化氮（NO）的产生具有强烈的抑制活性，并可用于预防和/或治疗人类和动物体内的NO介导的疾病。